Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
Long-Acting Insulins Claim a Slightly Larger Patient Share as a First-Line Therapy than the DPP-IV Inhibitors, According to a New Report from Decision Resources
BURLINGTON, Mass., Oct. 2, 2013 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through analysis of U.S. longitudinal patient-level claims data, dipeptidyl peptidase (DPP-IV) inhibitors claim the largest share among branded oral therapies of newly diagnosed type 2 diabetes patients across all three lines of therapy. DPP-IV inhibitors include Merck’s Januvia, Bristol-Myers Squibb/AstraZeneca’s Onglyza and Boehringer Ingelheim’s Tradjenta. According to Treatment Algorithms in Type 2 Diabetes, metformin and sulfonylureas continue to dominate first-line therapy use, while long-acting insulins are also more heavily used as a first-line therapy than the DPP-IV inhibitors, despite ADA/EASD guidelines recommending oral antidiabetic therapy prior to insulin administration.
The report also examines recently treated type 2 diabetes patients. This group represents patients treated in the first quarter of 2013 and reviews retrospective analysis of the preceding two years of therapy. The year-over-year trend analysis found that among recently treated patients use of rapid- and long-acting insulins continue to gain patient share, while DPP-IV inhibitors and GLP-1 receptor agonists’ patient share also steadily grow, which is likely to be at the expense of the PPAR-gamma agonists.
“The increased use of long-acting insulins such as Sanofi’s Lantus as a first line treatment may indicate that physicians are implementing more aggressive initial therapy than suggested in the treatment guidelines in an attempt to improve glycemic control,” said Decision Resources Analyst Eamonn O’Connor, Ph.D. “However, the increased use of rapid-acting insulins would indicate that current long-acting insulins are failing to provide complete 24-hour glycemic control.”
The analysis is part of Decision Resources’ Treatment Algorithms Insight series, which through examination of U.S. longitudinal patient-level claims data, provides exceptional insight into physicians’ prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease. Quarterly data analysis reveals progression rates of patients through each line of therapy, the share each brand commands by line of therapy and add-versus-switch patterns to key brands.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources